Indivior Pharmaceuticals vs Nasus Pharma
Indivior Pharmaceuticals and Nasus Pharma are similar in size: $1.24bn and $1.24bn of revenue in their latest fiscal years. Indivior Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 16.9% against -0.5%.
| Latest fiscal year | Indivior PharmaceuticalsINDV, 2025 | Nasus PharmaNSRX, 2025 |
|---|---|---|
| Revenue | $1.24bn | $1.24bn |
| Revenue growth | 4.3% | — |
| Net income | $210m | −$5.9m |
| Operating margin | 21.1% | -0.4% |
| Net margin | 16.9% | -0.5% |
| Return on equity | — | — |
| Free cash flow | −$93.0m | −$4.9m |
| Cash | $195m | $1.2m |
| Total debt | $319m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $11.0m | — |
| Employees | 838 | — |
| Market value | $4.43bn | $28.6m |
| Price vs our value range | Above our value range | — |
| Moat score | — | — |
| Insider trades, 12 months | 10 buys, 3 sales | 3 buys, 0 sales |